Literature DB >> 8164742

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma.

O Mandelboim1, G Berke, M Fridkin, M Feldman, M Eisenstein, L Eisenbach.   

Abstract

Many mouse and human tumours express major histocompatibility complex (MHC) class I-associated antigens that constitute targets for syngeneic cytotoxic T lymphocytes (CTL). Genes encoding such antigens were isolated from a mouse mastocytoma and from human melanomas by genetic methods. Isolation and characterization of MHC class I-associated peptides has enabled specific anchor residues to be identified that are typical of peptides that bind to distinct class I molecules. Moreover, CTL specific to particular MHC-peptide combinations have been used to identify naturally occurring antigenic peptides in cell extracts and enabled them to be sequenced directly. Most known MHC ligands are of viral origin or are self peptides derived from normal proteins. Here we use total acid extraction and repeated fractionation to isolate and sequence Lewis lung carcinoma (3LL)-specific peptide(s), which shows sequence homology to the connexin 37 protein. Synthetic octamers based on these sequences bind to 'empty' H-2Kb molecules on RMA-S cells, sensitize RMA-S cells to lysis by specific anti-3LL CTL, and induce anti-tumour CTL. The tumour-associated peptide originates from mutated connexin 37 expressed in 3LL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164742     DOI: 10.1038/369067a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  59 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

Authors:  E Z Wolpert; M Petersson; B J Chambers; J K Sandberg; R Kiessling; H G Ljunggren; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 3.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

5.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P G Coulie; F Lehmann; B Lethé; J Herman; C Lurquin; M Andrawiss; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 6.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

7.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

8.  Getting personal with neoantigen-based therapeutic cancer vaccines.

Authors:  Nir Hacohen; Edward F Fritsch; Todd A Carter; Eric S Lander; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

9.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

10.  Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects.

Authors:  Y Omori; M Mesnil; H Yamasaki
Journal:  Mol Biol Cell       Date:  1996-06       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.